With an aim to screen and detect cervical cancer at early stage, the BD (Becton, Dickinson and Company) Life Sciences-Diagnostic Systems, a leading global medical technology company has introduced BD SurePathTM Direct to Slide.
Based on the concept of Liquid based Cytology technique, this test enables detection of pre-cancerous lesions, atypical cells and all other cytologic categories. BD SurePathTM Direct to Slide will offer availability of residual sample for conducting important additional follow up tests without the need for repeat sampling.
Talking about the development, Pavan Mocherla, Managing Director, BD–India said, “Early detection of cervical cancer and its malignant precursors is imperative for survival. In India where women’s health is a priority, we are glad that BD SurePathTM DTS will be able to enhance the standard of patient care, representing the next milestone in cervical cancer screening.”
“BD’s cancer diagnostic capabilities focus on improving health outcomes for patients by providing laboratories with solutions that improve quality, enhance laboratory system productivity and inform medical decisions,” he further stated.
Traditionally, conventional pap smear, a simple and quick test has been the mainstay for cervical cancer screening. However, this method has limitations in preparation technique and its ability to detect every abnormality, hence the need to move towards a better and efficient technique.
As innovation and research continues in battling the increasing burden of cervical cancer, new technologies such as Liquid Based Cytology (LBC) have emerged as superior screening methods.
“With the launch of DTS-a simplified LBC solution, access to quality cervical cancer screening will increase and we recommend that an early diagnosis through screening by LBC can significantly enhance the chances of timely and successful treatment,” Dr Jaideep Malhotra, President-FOGSI2018 said.
In India cervical cancer is the second most common cancer among women between 15 and 44 years of age. Every year 122844 women are diagnosed with cervical cancer.
Dr. Minaxi Desai, Ex Director, Manchester Cytology Centre, Manchester Royal Infirmary, UK added, “Given that cervical cancer ranks as the 2nd most frequent cancer among women in India, it is a time that screening should become a part of their routine health check-up.”
“Women undergoing screening should opt for Liquid Based Cytology (LBC) as a screening test since it has demonstrated ability to detect abnormal cells at the initial stages of precancer thus, preventing cervical cancer from progressing and ensuring cure which detected and treated early enough,” Desai added.